4-Oxo Cyclophosphamide-d8
| Product Name | 4-Oxo Cyclophosphamide-d8 |
|---|---|
| Alternate Names | Cyclophosphamide Stable Isotopes, Stable Isotopes of Cyclophosphamide |
| CAT No. | CS-P-07356 |
| CAS No. | 27046-19-1 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Cyclophosphamide |
| Therapeutic | Immunosuppressants |
| Smileys | O=[P](NC1=O)(OCC1)N(C([2H])([2H])C([2H])([2H])Cl)C([2H])([2H])C([2H])([2H])Cl |
| Canonical Smiles | C1COP(=O)(NC1=O)N(CCCl)CCCl |
| InchIKey | VBMZHOCORXMDJU-UHFFFAOYSA-N |
| Inchl | InChI=1S/C7H13Cl2N2O3P/c8-2-4-11(5-3-9)15(13)10-7(12)1-6-14-15/h1-6H2,(H,10,12,13) |
| IUPAC | 2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-one |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
4-Oxo Cyclophosphamide-d8 is a deuterated version of 4-Oxo Cyclophosphamide, a well-known anticancer drug used in the treatment of various types of cancers. The deuterium substitution on the molecule's structure is intended to improve the drug's pharmacokinetic properties, making it more effective and safer to use.
The chemical structure of 4-Oxo Cyclophosphamide-d8 consists of a cyclophosphamide core, which is a prodrug of the alkylating agent phosphoramide mustard. The deuterium substitution on the molecule's structure is located at the C-4 position of the cyclophosphamide ring, which is the site of the drug's hydroxylation and activation by hepatic microsomal enzymes.
4-Oxo Cyclophosphamide-d8 is administered intravenously and undergoes rapid hydrolysis in the body to form its active metabolite, phosphoramide mustard. Phosphoramide mustard then alkylates DNA, leading to inter-strand cross-link formation and ultimately cell death.
The deuterated version of this drug has been shown to have a longer half-life in the body and also reduces the risk of toxic side effects that are associated with the non-deuterated version of the drug.
In conclusion, 4-Oxo Cyclophosphamide-d8 is a promising anticancer drug that is being developed to improve the efficacy and safety of the original drug. Deuterium substitution on the molecule's structure improves the drug's pharmacokinetic properties, making it a better option for cancer treatment.
Get an Instant Quote
Related Compounds
Cyclophosphamide D6 | Cyclophosphamide D8 | N-Dechloroethyl Cyclophosphamide-d4 | Cyclophosphamide D4 |